Category Archives: Cell Biology

The coronavirus may live longer on some surfaces than previously believed. Here’s what that means – Salon

Scientists already know that the novel coronavirus, which causes the disease COVID-19, is primarily transmitted through airborne particles known as aerosols that are either inhaled or ingested. One lingering question, though, has been how long the disease can survive on surfaces after landing there. A new study has a potentially troubling answer namely, that the virus can stay on surfaces like banknotes, glass and stainless steel for up to four weeks.

The study found that fomites, or objects that are likely to carry infection, can contain live specimens of the novel coronavirus for weeks. These include "high contact surfaces such as touchscreens on mobile phones, bank ATMs, airport check-in kiosks and supermarket self-serve kiosks all acting as fomites for the transmission of viruses," a group of scientists from Australia's national science agency, theCommonwealth Scientific and Industrial Research Organisation (CSIRO), wrote in their study. Published in the Virology Journal on Monday, the researchers argued that the SARS-CoV-2 virus "remains viable" for 28 days or longer when it dries on "non-porous" surfaces, meaning that it would be possible to get infected the novel coronavirus in a room with a conventional temperature and humidity level(68F and 50% humidity).

They note that the SARS virus, a related coronavirus, also managed to regain its infectiousness after remaining dried up on plastic for 28 days at room temperature.

That has implications particularly for the kinds of things that people touch everyday and trade between each other, particularly currency. As the authors explain, money is regularly passed between large groups of people, and banknotes made of paper and polymer can both carry live specimens of the novel coronavirus."The persistence of virus on both paper and polymer currency is of particular significance, considering the frequency of circulation and the potential for transfer of viable virus both between individuals and geographic locations," the authors explain.

Debbie Eagles, deputy director of the the Australian Centre for Disease Preparedness and one of the paper's co-authors, told CNET that their study reinforces the existing consensus that there is a"need for good practices such as regular handwashing and cleaning surfaces."

Prior to this paper, scientists did not always believe that the novel coronavirus could survive on surfaces for very long. A study from the New England Journal of Medicine in March speculated that the virus could survive for up to 72 hours on plastic, for up to 48 hours on stainless steel and for up to 24 hours on cardboard. Carolyn Machamer,a professor of cell biology at the Johns Hopkins School of Medicine, explained to the university's tech hub that "you are more likely to catch the infection through the air if you are next to someone infected than off of a surface. Cleaning surfaces with disinfectant or soap is very effective because once the oily surface coat of the virus is disabled, there is no way the virus can infect a host cell." A Chinese doctor, Wang Zhou MD, expressed a similar view in March, writing that viruses can survive "for several hours on smooth surfaces" and"if the temperature and humidity permit, they can survive for several days."

Dr. Mark McKinlay, the director of the Center for Vaccine Equity at The Task Force for Global Health and who is working closely with the CDC in its response to the virus, told Salon in May that breathing in the virus is still much more of a concern than transmitting the virus through touch.

"This new CDC guidance is clarifying that it is not as easy to become infected by the SARS-CoV-2 coronavirus from hard surfaces as it is to become infected via person-to-person contact, via respiratory droplets," McKinlay explained."That's why the guidance on social distancing is so important to follow. However, it does not mean that the virus is never spread through contact with surfaces, just that it is not the predominant route of transmission."

Still, even if breathing another's infected air appears to be the most probable path of infection, there is evidence of people acquiring the coronavirus by touching objects that other coronavirus-positive people havetouched. In New Zealand, which has so few cases of COVID-19 that contact tracers are able to precisely follow the path of infections, public health experts traced two recent infections to an elevator lift button and a trash can."This particular [trash] bin had a lid that required you to lift the lid," the island nation's director of public health,Dr Caroline McElnay, said at a press conference.

The recent evidence regarding the coronavirus' life on surfacessuggests that those with compromised immune systems or who are specifically concerned about transmission may want to be diligent about wiping down oft-touched public surfaces, currency, or avoiding touching these in the first place.

Read more:
The coronavirus may live longer on some surfaces than previously believed. Here's what that means - Salon

TreeFrog Therapeutics and Invetech Expand Partnership to Transition High-throughput Stem Cell Encapsulation Technology to GMP System for…

Since January 2019, TreeFrog Therapeutics has been collaborating with Invetech to turn its R&D encapsulation set-up into an automated single-use device for industrial bioproduction. "Our C-StemTM technology bridges stem cell biology and biophysics," explained Kevin Alessandri, CEO and CTO of TreeFrog Therapeutics. "We found in Invetech a team eager to confront a new technology, with strong execution capacities, supported by a step-by-step methodology to de-risk the project. As a matter of fact, they managed to deliver the prototype in time in April 2020, right in the middle of the COVID crisis."

The beta encapsulation system designed by Invetech meets its technical specifications with a throughput of 1,000 stem cell capsules per second. The first benefit of cell encapsulation is protection against hydrodynamic damages. This is instrumental to amplifying and differentiating fragile cells such as pluripotent stem cells in large-scale bioreactors. The second benefit of the capsule lies in the recapitulation of a biomimetic stem cell niche. In this micro-environment, pluripotent stem cells self-organize in a biomimetic 3D conformation, which promotes fast growth and accurate chromosome segregation.

"Today, our C-StemTM technologyreduces manufacturing costs by ten-fold, while dramatically improving batch-size, yields and genomic quality. All our efforts are now focused on bringing this technology to the clinic as fast as possible, by advancing a pipeline of cell therapies in co-development with leading pharmaceutical companies. In this context, our partnership with Invetech is critical to secure our roadmap to GMP compliance and to enhance even further the functionality, yield and processing conditions of our encapsulation device," said Maxime Feyeux, co-founder, CEO & CSO of TreeFrog Therapeutics.

"TreeFrog approached us with a very novel, early-stage technology that has progressed extremely fast and shows incredible promise," remarked David Kneen, Invetech's Vice President, Cell Therapy. "In under 18 months, our combined teams have transitioned C-StemTM from a bench-top proof-of-concept, to a closed and automated beta production system. It's been a great collaboration driven by our shared vision of commercializing this technology to enable the mass-production of cell therapies for patients in need."

Watch video

Download image

Press contacts

TreeFrog Therapeutics treefrog.fr

Pierre-Emmanuel Gaultier, Marketing & Communication Manager[emailprotected]+ 33 645 77 42 58

Invetech invetechgroup.com

Eeva Routio, Marketing Manager, Brand and Thought Leadership[emailprotected]+1858688 7136

SOURCE Invetech

Invetech

Originally posted here:
TreeFrog Therapeutics and Invetech Expand Partnership to Transition High-throughput Stem Cell Encapsulation Technology to GMP System for...

Researchers claim that ayahuasca tea helps the formation of new neurons – CT Post

Researchers claim that ayahuasca tea helps the formation of new neurons

Have you tried ayahuasca tea? A study led by researchers from the Complutense University of Madrid ( UCM ) found that the Amazonian drink traditionally used by shamans contributes to the formation of new neurons.

The study groups together the results of a four-year "in vitro" and "in vivo" experimentation carried out in mice, subjects that demonstrated greater cognitive capacity when treated with dimethyltryptamine (DMT), one of the components of ayahuasca, according to with Jos Antonio Lpez, researcher at the Faculty of Psychology of the Complutense University and co-author of the work.

Ayahuasca is obtained from a mixture between two Amazonian plants, the ayahuasca vine (Banisteriopsis caapi) and the chacruna bush (Psychotria viridis). "In ayahuasca, DMT binds to a type 2A serotonergic brain receptor, and that is when its hallucinogenic effect is enhanced. In this research, this binding is made with another receptor, sigma type, which does not have these effects. "Which greatly facilitates its future administration to patients," they explain in the study report.

According to Jos ngel Morales, researcher at the Department of Cell Biology of the UCM and the Center for Research in Network of Neurodegenerative Diseases (CIBERNED), the ability to modulate brain plasticity is an indication of a great therapeutic potential for a wide range of psychiatric disorders and neurological.

The death of certain neurons generates the symptoms of neurodegenerative diseases such as Parkinson's and Alzheimer's, the researchers said. However, the human being is capable of generating new neuronal cells but this always depends on other factors.

The challenge for scientists will be to activate the brain's ability to develop new neurons to replace those that die in people with neurodegenerative diseases.

"Ayahuasca" means "liana or rope of the spirits" and is used by South American shamans as traditional medicine in the Amazonian peoples.

Related:Researchers claim that ayahuasca tea helps the formation of new neuronsHealthcare is in Turmoil, But Technology Can Save Businesses BillionsHow to Pivot Your Product to Fight Covid-19

Original post:
Researchers claim that ayahuasca tea helps the formation of new neurons - CT Post

Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics and offer new treatment options for Multiple Myeloma patients |…

DetailsCategory: DNA RNA and CellsPublished on Thursday, 08 October 2020 15:15Hits: 87

NEW YORK, NY, USA and PARIS, France I October 08, 2020 I Cytovia Therapeutics ("Cytovia"), an emerging biopharmaceutical company, announces today that it has entered a research and licensing agreement with Inserm to develop NK engager bi-specific antibodies and iPSC CAR NK cell therapy targeting CD38, a key marker of multiple myeloma. The licensing agreement has been negotiated and signed by Inserm Transfert, the private subsidiary of Inserm, on behalf of Inserm (the French National Institute of Health and Medical Research) and its academic partners. Cytovia is licensing Inserm's CD38 antibody and Chimeric Antigen Receptor (CAR) patent and applying its proprietary NK engager bispecific antibody and iPSC CAR NK technology platforms. The research agreement will include evaluation of the therapeutic candidates at Hpital Saint-Louis Research Institute (Inserm Unit 976) under the leadership of Professors Armand Bensussan and Jean-Christophe Bories.

Dr Daniel Teper, Cytovia's Chairman and CEO commented: "We are delighted to partner with one of the top centers of excellence in the world for research and treatment in hematology. CD38 is a validated target and Natural Killer cells have significant cytotoxicity to Myeloma cells. We are looking forward to bringing promising new options to address the unmet needs of patients with Multiple Myeloma and aim for a cure."

Professor Armand Bensussan, Director of The Immuno-Oncology Research Institute at Hpital Saint-Louis added: "We have demonstrated the selectivity of our novel CD38 antibody in killing myeloma cells but not normal cells such as NK, T, and B cells. The activation of NK cells through NKp46 may enhance the efficacy of the bispecific antibody in patients not responsive to CD38 monoclonal antibody therapy. CD38 CAR NK is a promising approach forrelapsed/refractory patients and an alternative to CAR T therapies."

About Multiple MyelomaMultiple Myeloma is a currently incurable cancer, affecting a type of white blood cell known as plasma cells. It leads to an accumulation of tumor cells in the bone marrow, rapidly outnumbering healthy blood cells. Instead of producing beneficial antibodies, cancerous cells release abnormal proteins causing several complications. While symptoms are not always present, the majority of patients are diagnosed due to symptoms such as bone pain or fracture, low red blood cell counts, fatigue, high calcium levels, kidney problems, and infections. According to the World Cancer Research Fund, Multiple Myeloma is the second most common blood cancer, with nearly 160,000 new annual cases worldwide, including close to 50,000 in Europe. 32,000 in the US, and 30,000 in Eastern Asia. Over 95% of cases are diagnosed late, with a 5-year survival rate of 51%. Initial treatment comprises of a combination of different therapies, including biological and targeted therapies, corticosteroids, and chemotherapy, with the option for bone marrow transplants for eligible patients. Immunotherapy and cell therapy are the most promising new treatment option for Multiple Myeloma, with the potential for long term cancer remission.

About CAR NK cellsChimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR-NK cell therapy has demonstrated initial clinical relevance without the limitations of CAR-T, such as Cytokine Release Syndrome, neurotoxicity or Graft vs Host Disease (GVHD). Induced Pluripotent Stem Cells (iPSC) - derived CAR-NKs are naturally allogeneic, available off-the-shelf and may be able to be administered on an outpatient basis. Recent innovative developments with the iPSC, an innovative technology, allow large quantities of homogeneous genetically modified CAR NK cells to be produced from a master cell bank, and thus hold promise to expand access to cell therapy for many patients.

About CytoviaCytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem, and CytoImmune Therapeutics. Learn more at http://www.cytoviatx.com

About InsermFounded in 1964, the French National Institute of Health and Medical Research (Inserm) is a public science and technology institute, jointly supervised by the French Ministry of National Education, Higher Education and Research, and the Ministry of Social Affairs, Health and Womens Rights. Inserm is the only French public research institute to focus entirely on human health and position itself on the pathway from the research laboratory to the patients bedside. The mission of its scientists is to study all diseases, from the most common to the rarest. With an initial 2020 budget of 927.28 million, Inserm supports nearly 350 laboratories throughout France, with a team of nearly 14,000 researchers, engineers, technicians, and post-doctoral students. http://www.inserm.fr

SOURCE: Cytovia Therapeutics

The rest is here:
Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics and offer new treatment options for Multiple Myeloma patients |...

NTHU research could have significant impact on the treatment of dementia – News-Medical.net

Oct 8 2020

One of the causes of neurodegenerative diseases such as Parkinson's and Alzheimer's is the calcification of the basal nucleus of the brain, which blocks the membrane protein channels on the surface of brain cells, preventing the transmission of signal molecules and nutrients to the cells. A research team led by Professor Sun Yuh-Ju of the Institute of Bioinformatics and Structural Biology, working in conjunction with Chwan-Deng Hsiaos laboratory at Academia Sinicas Institute of Molecular Biology, has recently solved the mystery which has long surrounded the molecular structure of the phosphate transporter and their findings are expected to have a significant impact on research into the treatment of dementia. The teams research finding has been published in the August issue of Science Advances.

Professor Sun Yuh-Ju of the Institute of Bioinformatics and Structural Biology showing team member Tsai Jia-Yin how to grow a crystal. (Photo: Business Wire)

According to Sun, membrane proteins, such as receptors, transporters and channels, are responsible for transmitting signals and supplying energy to cells, and therefore play a very important role in the development of pharmaceuticals. Human phosphate transporter (hPiT) is an important membrane protein for transporting phosphate and sodium ions into brain cells. But pathological changes can block this transport, allowing calcium phosphate to precipitate on the surface of the cell membrane, which will eventually lead to calcification of the basal nucleus, thereby producing the neurodegenerative symptoms typical of Parkinsons disease and Alzheimers disease.

Sun said that analyzing the human phosphate transporter and locating the site of the patients variants are important in finding a treatment for brain calcification. The next step is to cooperate with physicians in designing drugs based on this structure, using computer calculations and simulations in conducting experiments to identify small chemical molecules effective in restoring the normal functioning of membrane proteins. Chwan-Deng Hsiao, who specializes in biophysics, played a key role in this innovative research. After Sun's research team analyzed the three-dimensional structure of the human phosphate transporter, Hsiao used an artificial cell membrane to determine whether a mutation at the target location would prevent the membrane protein from transporting phosphate.

There are more than 30,000 kinds of proteins in the human body, amongst which membrane proteins are the most important, and least understood, which is why Sun has made it the focus of her research. It took 5 years to analyze the molecular structure of the phosphate transporter.

The first step in analyzing the molecular structure of membrane protein is to cultivate the membrane protein crystal. Human phosphate transporter crystal that is only one-tenth the size of a sesame grain, Sun said that its angular, glittering, and translucent form contains important information on molecular structure, such that its more precious and beautiful than a diamond.

The team member in charge of growing the membrane protein crystals was Tsai Jia-Yin, a postdoctoral researcher at NTHUs Institute of Bioinformatics and Structural Biology.

Follow this link:
NTHU research could have significant impact on the treatment of dementia - News-Medical.net

New study traces the evolution of gill covers – ScienceBlog.com

The emergence of jaws in primitive fish allowed vertebrates to become top predators. What is less appreciated is another evolutionary innovation that may have been just as important for the success of early vertebrates: the formation of covers to protect and pump water over the gills. In anew study published in theProceedings of the National Academy of the Sciences (PNAS), USC Stem Cell scientists and their collaborators have identified a key modification to the genome that led to the evolution of gill covers more than 430 million years ago.

The scientists started by creating zebrafish with mutations in a gene called Pou3f3. Strikingly, fish lacking this gene, or the DNA element controlling its activity in the gills, failed to form gill covers. Conversely, zebrafish producing too much Pou3f3 developed extra rudimentary gill covers.

Intrigued by these findings, co-corresponding authorsGage CrumpandLindsey Barskecollaborated with scientists from several universities to explore whether changes in Pou3f3 might account for the wide variation in gill covers across vertebrates. Crump is a professor of stem cell biology and regenerative medicine at USC. Barske initiated the study in the Crump lab, and is now an assistant professor at Cincinnati Childrens Hospital Medical Center.

In jawless fish such as sea lampreys, which lack gill covers, the scientists found that the control element to produce Pou3f3 in the gill region is missing.

In contrast, in cartilaginous fish such as sharks and skates, the control element for Pou3f3 is active in all gills. Correspondingly, nearly all cartilaginous fish have a separate cover over each gill. In bony fish, including zebrafish, the control element produces Pou3f3 in one particular region, leading to a single cover for all gills.

Remarkably, we have identified not only a gene responsible for gill cover formation, said Crump, but also the ancient control element that allowed Pou3f3 to first make gill covers and then diversify them in cartilaginous versus bony fish.

Barske and Crump even showed that humans retain this control element, reflecting the presence of gill cover-like structures in human embryos that are inherited from our distant fish ancestors.

Additional authors were Peter Fabian, Pengfei Xu, Nellie Nelson, and Haoze Vincent Yu from USC; Tyler Square, David Jandzik, and Daniel M. Medeiros from the University of Colorado; and Christine Hirschberger from the University of Cambridge, UK; and J. Andrew Gillis from the University of Cambridge, UK, and the Marine Biological Laboratory, Woods Hole.

Funding was provided by the National Institute of Dental and Craniofacial Research (R35 DE027550, R00 DE026239, and R21 DE025940A), the National Institute on Deafness and Other Communication Disorders (R01 DC015829), the National Science Foundation (IOS 1744837), the A.P. Giannini Foundation, the Cincinnati Childrens Research Foundation, the Scientific Grant Agency of Slovak Republic (VEGA 1/0415/17), a Royal Society University Research Fellowship (UF130182), a Isaac Newton Trust award (14.23z), and a BBSRC Doctoral Training Partnership studentship. The bioinformatics software and computing resources were funded by the USC Office of Research, the USC Norris Medical Library, Cincinnati Childrens Research Foundation, and the Hearing Health Foundation.

Go here to see the original:
New study traces the evolution of gill covers - ScienceBlog.com

Cell Perturbation System Could Have Medical Applications – Technology Networks

Cell lines injected with free nucleic acid are widely used for drug discovery and disease modeling. To avoid genetically mixed cell populations, investigators use dilution techniques to select single cells that will then generate identical lines. However, the route of limiting dilutions is tedious and time consuming.

A new study by Northwestern researchers shows how Nanofountain Probe Electroporation (NFP-E), a tool that delivers molecules into single-cells, could solve that issue, and could lead to new applications for drug screening and designing patient-specific courses of treatment.

The team, led by Northwestern Engineering's Horacio Espinosa and including Joshua Leonard, demonstrates the versatility of NFP-E -- which introduces DNA or RNA into cells using electricity. It can also deliver both proteins and plasmids in a variety of animal and human cell types with dosage control. The team included John Kessler, the Ken and Ruth Davee Professor of Stem Cell Biology and professor of neurology and pharmacology at the Northwestern University Feinberg School of Medicine.

The new method can be used to study disease or for cell therapy. In the former, the genome is manipulated. In the latter, gene-editing occurs in cells such as T-cells to treat cancer with immunotherapies.

By employing single-cell electroporation, the process of introducing DNA or RNA into single cells using a pulse of electricity, which briefly open pores in the cell membrane, their work shows how NFP-E achieves fine control over the relative expression of two co-transfected plasmids. Moreover, by pairing single-cell electroporation with time-lapse fluorescent imaging, their investigation reveals characteristic times for electro-pore closure.

"We demonstrated the potential of the NFP-E technology in manipulating a variety of cell types with stoichiometric control of molecular cargo that can be used for conducting a wide range of studies in drug screening, cell therapies, and synthetic biology," said Espinosa, James N. and Nancy J. Farley Professor in Manufacturing and Entrepreneurship and professor of mechanical engineering and (by courtesy) biomedical engineering and civil and environmental engineering.

Currently, biomolecules can be delivered into cells in numerous ways: viral vectors; chemical carriers, such as cell-penetrating peptides and polymer nano-capsules; lipofectamine, and bulk electroporation.

"There exist a number of strategies for delivering biomolecules into cells, but each has its limitations," said Leonard, associate professor of chemical and biological engineering and Charles Deering McCormick Professor of Teaching Excellence. "For instance, chemical carriers confer relatively slow delivery and can be toxic to the cell; viral vectors are often efficient but can induce adverse immune responses and insertional genotoxicity. Use of any traditional method often requires substantial effort to optimize the protocol depending on the cell type and molecule to be delivered, and, therefore, a readily generalizable biomolecule delivery strategy would offer some meaningful advantages."

The new NFP-E system enables single-cell delivery of DNA, RNA, and proteins into different immortalized cell lines as well as primary cells with more than 95 percent efficiency and more than 90 percent cell viability.

"The results indicate that the cell membrane resealing time scales non-linearly with the pulse voltage and the number of electroporation pulses, reaching a maximum at intermediate values," Espinosa said. "That means long pulsing times or high voltages appear not to be necessary for efficient molecular transport across cell membranes. That feature is important in obtaining high transport efficiency while keeping cell toxicity to a minimum."

Using single-cell electroporation technology, the researchers were able to understand transport mechanisms involved in localized electroporation-based cell sampling. One obstacle to nondestructive temporal single-cell sampling is the small amounts of cytosol -- the fluid inside cells -- that are extracted, which makes it challenging to test or detect RNA sequences or proteins.

Research showed that the scaling of membrane resealing time is a function of various electroporation parameters, providing insight into post-pulse electro-pore dynamics.

"The work addresses the need to understand ways to increase the cytosol-sampled amount, without adversely affecting cells," Espinosa said. "That can guide the research community in designing experiments aimed at electroporation-based sampling of intracellular molecules for temporal cell analysis."

This research is related to previous work that developed a minimally invasive method to sample cells that can be repeated multiple times. That earlier investigation, which used electric pulses to extract enzymes from the cytosol, assisted understanding of the kinetics of pore formation and closure.

Reference: Nathamgari SSP, Pathak N, Lemaitre V, et al.Nanofountain Probe Electroporation Enables Versatile SingleCell Intracellular Delivery and Investigation of Postpulse Electropore Dynamics. SmallBC, 2020. doi:10.1002/smll.202002616

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the article here:
Cell Perturbation System Could Have Medical Applications - Technology Networks

OncoHost Data on Host Immunotherapy Response to be Presented This Week – Technology Networks

OncoHost, announced on 5th October that Professor Yuval Shaked, co-founder and Chief Scientific Advisor at OncoHost, and Professor of Cell Biology and Cancer Science at the Technion Israel Institute of Technology, will deliver a presentation titled A Proteomics-Based Platform for Predicting Response to Immunotherapy and Personalizing Treatment Plans at the MAP 2020 Virtual Congress - ESMO this Friday, October 9th at 17:20 PM CEST.

The presentation will show how through the analysis of host response profiles (i.e. the patients reaction), oncologists may be able to harness this information to better predict clinical outcomes and suggest the ideal combination treatment with immunotherapy.

Despite major clinical success, immunotherapy treatments have demonstrated efficacy in only a small proportion of patients with non-small cell lung cancer (NSCLC), said Prof. Yuval Shaked. OncoHosts studies have indicated that individual host response to anti-cancer treatment can generate pro-tumorigenic activities and support tumor re-growth and spread. It is therefore vital to analyze and earlier predict host response to treatment in order to improve outcomes and reduce unnecessary side effects experienced by so many patients.

Using machine learning (ML)-based analysis and algorithms to identify highly predictive cohort-based proteomic signatures in patients, personalized response prediction can be used to improve precision medicine in oncology. Personalized treatment plans can then be created through information based on cohort-based statistical analysis, personalized adaption and finally, translation to clinically relevant targets.

Prof. Shakeds presentation will include a real-life case study on whom a Host Response profile analysis was performed, and will be followed by a live Q&A.

MAP is the leading congress in precision medicine in oncology in Europe, established by key opinion leaders in the field. The name of the Congress was recently changed into Molecular Analysis for Precision Oncology to better reflect its aims of focusing on science, translational research, education and collaboration. This years event will be held virtually on October 9-10.

Here is the original post:
OncoHost Data on Host Immunotherapy Response to be Presented This Week - Technology Networks

OncoHost to Present Data on Predicting Host Response to Immunotherapy at the MAP 2020 Virtual Congress – ESMO – PRNewswire

BINYAMINA, Israel, Oct. 5, 2020 /PRNewswire/ -- OncoHost, a global leader in host response profiling for improved personalized cancer therapy, announced today that Professor Yuval Shaked, co-founder and Chief Scientific Advisor at OncoHost, and Professor of Cell Biology and Cancer Science at the Technion Israel Institute of Technology, will deliver a presentation titled A Proteomics-Based Platform for Predicting Response to Immunotherapy and Personalizing Treatment Plans at the MAP 2020 Virtual Congress - ESMOthis Friday, October 9th at 17:20 PM CEST.

The presentation will show how through the analysis of host response profiles (i.e. the patient's reaction), oncologists may be able to harness this information to better predict clinical outcomes and suggest the ideal combination treatment with immunotherapy.

"Despite major clinical success, immunotherapy treatments have demonstrated efficacy in only a small proportion of patients with non-small cell lung cancer (NSCLC)," said Prof. Yuval Shaked. "OncoHost's studies have indicated that individual host response to anti-cancer treatment can generate pro-tumorigenic activities and support tumor re-growth and spread. It is therefore vital to analyze and earlier predict host response to treatment in order to improve outcomes and reduce unnecessary side effects experienced by so many patients."

Using machine learning (ML)-based analysis and algorithms to identify highly predictive cohort-based proteomic signatures in patients, personalized response prediction can be used to improve precision medicine in oncology. Personalized treatment plans can then be created through information based on cohort-based statistical analysis, personalized adaption and finally, translation to clinically relevant targets.

Prof. Shaked's presentation willinclude a real-life case study on whom a Host Response profile analysis was performed, and will be followed by a live Q&A.

MAP is the leading congress in precision medicine in oncology in Europe, established by key opinion leaders in the field. The name of the Congress was recently changed into Molecular Analysis for Precision Oncology to better reflect its aims of focusing on science, translational research, education and collaboration. This year's event will be held virtually on October 9-10.

About OncoHost

OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. Utilizing proprietary proteomic analysis, the company aims to understand patients' unique response to therapy and overcome one of the major obstacles in clinical oncology today resistance to therapy. OncoHost's Host Response Profiling platform (PROphet) analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient (i.e., the host) in response to a given cancer therapy. This proteomic profile is highly predictive of individual patient outcome, thus enabling personalized treatment planning. PROphet also identifies potential drug targets, advancing the development of novel therapeutic strategies as well as rationally based combination therapies.

For more information, visithttp://www.oncohost.com

Follow OncoHost onLinkedIn

OncoHost Media Contact: Ellie HansonFinn Partners [emailprotected]+1 929-222-8006

SOURCE OncoHost

https://oncohost.com/

View original post here:
OncoHost to Present Data on Predicting Host Response to Immunotherapy at the MAP 2020 Virtual Congress - ESMO - PRNewswire

Agendia, HiSS Diagnostics and PathoNext offer local MammaPrint and BluePrint testing for breast cancer patients in Germany – Monterey County Weekly

IRVINE, Calif., Oct. 6, 2020 /PRNewswire/ -- Agendia Inc., a world leader in precision oncology for breast cancer, announced today the availability of local testing for its CE-marked MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping tests, provided by PathoNext lab in Leipzig, Germany. Breast cancer patients in Germany will now have access to state-of-the art genomic profiling in their own country.

The trend towards precision oncology ensures that more physicians than ever before are integrating genomic testing into their routine clinical practice. This essential information helps them to truly individualize how they manage their patients' treatment regimen tominimize unnecessary treatment, retain quality of life and ensure the best possible outcomes.

MammaPrint analyzes 70 genes most associated with breast cancer recurrence to provide a binary Low or High Risk of cancer recurrence result, while BluePrint analyzes 80-genes which classify a patient's breast cancer into functional molecular subtypes. These tests have historically been perfomed via microarray at Agendia's laboratory in Irvine, California, and Agendia continues to provide a centralized testing service.

However, more and more countries request local testing for reimbursement of tests. To address the specific need for testing in other countries outside of the Agendia central laboratory, the next-generation sequencing (NGS)-based MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit has been developed. This CE-marked kit is an RNA-sequencing based version of the existing microarray-based MammaPrint and BluePrint tests. Analytical and clinical validity of the NGS-kit have been demonstrated and published in peer-reviewed journals.

PathoNext in Germany will partner with Agendia to run the tests and co-partner with HiSS, Agendia's distributor in Germany. PathoNext will leverage its existing infrastructure to run MammaPrint and BluePrint in its own labs, using NGS instruments to analyze patient samples. HiSS covers a broad range of specialties, including oncology and cell biology. Both companies will work together to offer patients in Germany access to MammaPrint and BluePrint testing.

Mark Straley, CEO of Agendia, commented,"We are very pleased to have our NGS-kit available in the German market. We are confident that PathoNext will deliver the same high-quality performance as they do with their other tests. Together, we will bring Agendia's high-quality testing to the nearly 25,000 women annually diagnosed with breast cancer in Germany."

Breast cancer is the most common cancer in women, affecting one in eight in Europe with 355,000 new cases per year. The quality-of-life and cost benefits of identifying women who may not have significant benefit from chemotherapy are considerable. Providing both centralized and decentralized testing options increases patient access to the MammaPrint and BluePrint tests.

Prof. Dr. Jrg Gabert, CEO of PathoNext, added,"With the growing breast cancer burden globally, and increasing incidence of diagnoses, Agendia's MammaPrint and BluePrint are a perfect complement to our molecular pathology division. We are pleased to help breast cancer patients, both in obtaining an appropriate diagnosis, and in the choice of a fully personalized treatment."

About PathoNextPathoNext GmbH is a biotechnology company which specializes in the new techniques of high throughput DNA sequencing. They are generally summarized under the term next-generation sequencing (NGS). The methods are used to identify genetic changes for the detection of relevant point mutations, insertions, deletions, translocations and microsatellite instabilities and revolutionized wide areas of pathology and oncology. Diseases can be better differentiated using NGS and the therapeutic success of medication - for example in the case of tumor diseases - can be better assessed.

In addition, PathoNext is concerned with the bioinformatic evaluation of big data and the development of special gene panels for reliable detection of genetic changes. The company is accredited according to DIN ISO 17025. For information about PathoNext please visitwww.pathonext.de.

About HiSSHiSS Diagnostics GmbH in Freiburg, Germany with 30 years of experience as a trusted supplier of diagnostics products for oncology and molecular biology and is a long-standing distribution partner of Agendia. Previously a competent advisor for German patients regarding the realization of MammaPint and BluePrint Tests, HiSS was looking for a suitable laboratory to perform the tests within Germany and found a competent partner in PathoNext. Thus, the legal requirements for reimbursement are met. HiSS Diagnostics is accredited according to ISO 13485:2016. For more information about HiSS Diagnostics please visit http://www.hiss-dx.de.

About AgendiaAgendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the most effective treatment decisions. The company currently offers two commercially-available genomic profiling tests, supported by clinical and real world evidence. MammaPrint, the 70-gene breast cancer recurrence assay, and BluePrint, the 80-gene molecular subtyping assay, provide a comprehensive genomic profile and the data physicians need to make more informed decisions in the pre- and post-operative treatment settings. By developing evidence-based novel genomic tests and conducting groundbreaking research while building an arsenal of data that will help treat cancer, Agendia aims to improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.

For more information on Agendia's assays and ongoing trials, please visit http://www.agendia.com.

Follow this link:
Agendia, HiSS Diagnostics and PathoNext offer local MammaPrint and BluePrint testing for breast cancer patients in Germany - Monterey County Weekly